Seeking Alpha

nicksanta

nicksanta
Send Message
View as an RSS Feed
View nicksanta's Comments BY TICKER:
Latest  |  Highest rated
  • Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market [View article]
    No frustration here. This takes time. I'll wait.
    May 21, 2015. 11:46 AM | Likes Like |Link to Comment
  • Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market [View article]
    Sell away folks. Buying opportunity for me.
    May 20, 2015. 10:56 PM | 1 Like Like |Link to Comment
  • Integral's (ITKG) CEO Doug Bathauer on Q3 2015 Results - Earnings Call Transcript [View article]
    Absolutely outstanding call.
    May 18, 2015. 10:34 PM | 1 Like Like |Link to Comment
  • Why I Like Provectus Better At $0.90 A Share Than I Did At $0.80 [View article]
    gibbiesmalls, phase 3 has started.
    May 18, 2015. 08:52 AM | Likes Like |Link to Comment
  • Why I Like Provectus Better At $0.90 A Share Than I Did At $0.80 [View article]
    If you stop reading "stories" you would know why it took 4 years.
    May 14, 2015. 11:52 AM | 2 Likes Like |Link to Comment
  • Let Me Tell You A Story About Pfizer [View article]
    Answers to some of your questions can be found on your own. Answers to others I'm waiting on as well, but I'm not turning away until they come. For a small R&D biotech to have such potential in regards to safety and efficacy is impressive. Things have moved slowly and mgmt made some mistakes. Nobody is perfect. But lately they are doing well and a lot should happen in 2015. I think they will happen. You don't and that's fine. That is the difference...opinion plays a big part. I attempted to see if you changed your mind based on fact. But you want to wait for data that may come when it is too late. I am invested now.

    Today's combo patent with Pfizer is a big step in the right direction. Not because it was with Pfizer. Because the patent is key. Many options ahead.
    Apr 20, 2015. 12:46 PM | 1 Like Like |Link to Comment
  • Let Me Tell You A Story About Pfizer [View article]
    I know of one SA Contributor who makes asinine comments. See above.

    Thank you once again for proving to all of us what type of "contributor" you are: one-sided, shortsighted, unwilling to answer direct questions and unwilling to consider all the facts to make a decision.

    Keubiko knows 3 cigar smokers who lived to 100. So does this mean cigar smoking is the fountain of youth? He thinks so.

    Over 50,000 people lived to 100 in 2010. Did they all smoke cigars?

    One large cigar has as much tobacco as an entire pack of cigarettes.

    480,000 people die each year from cigarettes, including deaths from second hand smoke...in the United States.

    1 in 5 people die from tobacco use in the United States.

    Overall, it doesn't look good for Keubiko's hypothesis that cigars are the fountain of youth. In fact, the opposite seems to be true. But we already know that. This was simply an exercise in the importance of using all the facts and giving them all thought before making a decision.

    With that said, when it comes to unresectable liver cancer, the facts are clear...the 5 year survival rate is under 15%. It is much worse for HCC...patients are only given 3 to 6 months to live.

    Luckily, PVCT ran a small phase 1 study of 10 patients with either HCC or cancer metastatic to the liver where surgery was not an option. This was in January of 2011. Over 4 years later 7 are still alive with no cancer after a single injection of PV-10 to a liver tumor.

    Small sample...yes, but statistically speaking only 1 should be alive at this point. They had no other treatment except PV-10. If it was just a red food dye, then all 10 would be dead by now. But Keubiko thinks otherwise. First it was lack of overall survival data. Now that it is available, it is not good enough. Now it's lack of a "proper" study. Sounds like it will always be something. Shame.
    Apr 19, 2015. 10:10 PM | 1 Like Like |Link to Comment
  • Let Me Tell You A Story About Pfizer [View article]
    My reason for this is because you are a SA Contributor and a lot of people follow you. I think you need to be held accountable for making specific comments here and elsewhere as to why you think PV-10 is "snake oil". One of those specific comments was the missing overall survival data. Now that we have it you say only a fool believes in phase I data. That is an asinine thing to say, yet you call me a fool.

    The bottom line is this...I provided appropriate survival rates for unresectable liver cancer compared to your generic statistic about all cancers. You ignored it. I will repeat...Overall, 5 year survival in liver cancer, according to The American Cancer Society, is 15%. It is lower for those with unresectable cancer. Liver cancer is generally considered incurable if it can not be removed surgically. PV-10 treated unresectable liver cancer patients.

    Phase I or not, the fact that 7 patients are still alive (up to 4 years and 2 months later) is remarkable. They should be dead. PV-10 has kept them alive. Why do you ignore the significance of this? Because it is phase I? Again, they should be dead. This wasn't random chance that they didn't die. PV-10 was injected into a liver tumor, the tumor is gone and all others (colon, ovary, etc) where the cancer originated are also gone. Think that might be a reason they are still alive? Have an original thought of your own here instead of making comments like "show me a double-blind, randomized, placebo-controlled statistically powered clinical trial" and "enjoy your snake oil".

    Further trials will need to be done and they will be. I'm not denying the standard clinical trial process. But for now the phase I data speaks for itself...PVCT moved the needle on overall survival and you didn't think they could.
    Apr 18, 2015. 10:54 PM | 1 Like Like |Link to Comment
  • Let Me Tell You A Story About Pfizer [View article]
    Of course you didn't. Didn't expect you to admit you were wrong. And now you are still wrong. Keep putting it in writing though. As a Contributor to SA it will help us know who to listen to and who to ignore.

    So I see you decided to play semantics. Yes, I did say after 50 months instead of up to. My mistake. But you failed to comment on the significance of this feat. Some patients are still alive up to or near 50 months after treatment. Still alive! Overall Survival! Not having this data was your main arguement!

    Now that your own demands for data have been met, how can you not agree this is a game changer? How? You say it is meaningless, but won't say why.

    BTW, your comment about 5 year survival does not apply to the liver data. Here's why...

    Some of these patients had liver cancer secondary to a primary cancer somewhere else in their body. Liver metastases are often the cause of death when other cancers started the process. The patients enrolled had to have cancer in their liver that was too large or dangerously located to be treated with surgical removal. Overall, 5 year survival in liver cancer, according to The American Cancer Society, is 15%. It is lower for those with unresectable cancer. Liver cancer is generally considered incurable if it can't be removed surgically. (This paragraph includes words from an article written by Dr. Alan Ross where he included links to back it up. I suggest you read it.)

    Lastly, you said the following: "I put a very low probability that they will move the needle on overall survival."

    Well, they did...big time. So using your logic you should change your mind. Why won't you?
    Apr 17, 2015. 09:59 PM | 2 Likes Like |Link to Comment
  • Let Me Tell You A Story About Pfizer [View article]
    Keubiko,

    I'm curious if you have changed your mind now that liver data was provided recently. 7 of 10 patients treated with PV-10 are still alive after 50 months. Small number yes, but it was only a phase 1 study. And one patient died of a heart attack unrelated to PV-10.

    This is remarkable data for two reasons: most do not survive liver cancer after a year and those treated with PV-10 also saw their original tumors (not injected) go away. Not a bad result for a food dye.

    So I ask again and include your comments below for reference...what say you now? Using your logic below you should have a high price target now...

    "PV-10 is used only for Stage III and later melanoma."

    "Progression free survival and overall survival are what matters."

    "I see little that is encouraging on that front, even in the early data (e.g. progression free survival vs. those that had untreated lesions)."

    "Again, melanoma in the lymph node system already."
    Apr 16, 2015. 09:21 PM | 1 Like Like |Link to Comment
  • NanoTech Entertainment: On The Verge Of Something Big? [View article]
    And BTW lowenstein...

    Fact: up 6.25% today. my oh my!

    See how silly that is?
    Apr 14, 2015. 11:08 AM | Likes Like |Link to Comment
  • NanoTech Entertainment: On The Verge Of Something Big? [View article]
    lowenstein, you guys need new catch phrases. "My oh my!" Really??? I see that used by almost every person who is 100% negative a stock. And posting when the pps drops??? You stick out too much now. Easily identifiable. Comon, you're better than that! Show me what you can come up with!
    Apr 14, 2015. 08:46 AM | Likes Like |Link to Comment
  • NanoTech Entertainment: On The Verge Of Something Big? [View article]
    Matt first wrote about ELTP on 9/11/13. The pps was about 14 cents. It is now in the 20s and was almost a dollar last year. Where exactly is the precipitous decline?

    Maybe this is part of the game you guys play...bash a person and his stocks with little to no accuracy so that readers have no choice but to like the stock. It's the only thing that makes sense. These are solid picks for long term growth. Therefore, you must be a shareholder.
    Apr 11, 2015. 10:37 PM | Likes Like |Link to Comment
  • NanoTech Entertainment: On The Verge Of Something Big? [View article]
    Your still talking?
    Apr 9, 2015. 05:42 PM | Likes Like |Link to Comment
  • Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market [View article]
    Joseph,

    I can only go by the company's guidance announced in February. See below. I expect the pps to eventually rise to at least $2, with potential to go much much higher. But who really knows. All I know is it will be much more than 22 cents!! I'm basing that on the current value of the company that Elite announced last year or so when they used an outside consultant to evaluate them. The pps could move after results are announced, so buying now is a good option. But the real push may not happen until the FDA approves the NDA in 2016. And I'm more than willing to wait that long to see how high we can go.

    Elite Pharmaceuticals Provides Guidance on Phase III Study for ELI-200
    NORTHVALE, N.J., Feb. 17, 2015 (GLOBE NEWSWIRE)

    Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP) announced guidance today regarding the Company's Phase III trial for ELI-200, an abuse deterrent opioid product. Elite has submitted a study protocol to the FDA and dosing for the study is expected to begin shortly after the FDA comments on the protocol are received by Elite. The Company anticipates that it will receive the FDA comments by mid-March and that dosing will take approximately eight weeks to complete.

    The Phase III study is a multi-center, randomized, multiple-dose, double-blind, placebo-controlled, parallel group, study to evaluate the efficacy and safety of abuse deterrent ELI-200 for the treatment of adults with moderate to severe pain following surgery. The study will enroll approximately 150 patients. We anticipate filing the ELI-200 NDA in Q3 and therefore expect the NDA review by FDA to be completed by early 2016.

    Two additional studies will also be completed to support product labeling. The first study is a Phase I, open-label, randomized, single-dose, three-way crossover study to compare the bioavailability of ELI-200 to the reference product under fed conditions in healthy volunteers. Dosing of this study has been completed. The second study is a randomized, double-blind, multiple-dose, parallel group study to evaluate the potential withdrawal effects following administration of ELI-200 versus the reference product in methadone-maintained opioid-dependent subjects. The dosing of the withdrawal study has been initiated. Results and reports for both studies are expected to be available prior to the completion of the Phase III study.

    "We are pleased with the guidance we have received from the FDA and the clear regulatory pathway forward for ELI-200. Our filing date is expected to be in the third quarter of this year, and we are encouraged that the FDA review leading to approval is expected to be completed by early 2016," said Nasrat Hakim, President and CEO of Elite Pharmaceuticals. "In preparation for the launch of ELI-200, we are also expanding our manufacturing facility and adding capacity. ELI-200 is the first of our abuse-deterrent opioid pipeline of products under development utilizing our proprietary technology platform."
    Apr 9, 2015. 10:53 AM | Likes Like |Link to Comment
COMMENTS STATS
311 Comments
334 Likes